Avttx
6 known investors
AVTTX is a clinical-stage company developing gene therapy treatments for retinal and ophthalmologic diseases. The company leverages adeno-associated virus (AAV) technology to address unmet medical needs in vision care.
Also known as Ashvattha Therapeutics · AVTTX
Founders & leadership
Investors · 6
Company profile
researched Aug 2026Ashvattha Therapeutics (avttx.com) is a clinical-stage biopharmaceutical company developing a class of intracellular targeted precision nanomedicines based on its hydroxyl dendrimer (HD) technology. The company states its therapeutics traverse tissue barriers and are selectively taken up by inflamed tissues, targeting activated cells in regions of inflammation. Its stated therapeutic focus spans ophthalmology, neurology, and inflammatory diseases.
In ophthalmology, the company has designed an anti-angiogenic nanomedicine intended to cross the blood-retinal barrier and selectively target activated microglia, macrophages, and retinal pigment epithelial cells in the eye. Its lead disclosed candidate is migaldendranib (MGB), described as a first-in-class subcutaneous nanomedicine and next-generation tyrosine kinase inhibitor being developed for diabetic macular edema (DME).
Traction
The company reported positive Phase 2 results for migaldendranib in diabetic macular edema, including 40-week topline data, and stated that the FDA agreed with its Phase 2b/3 clinical design, including the primary endpoint and development approach, allowing two studies to be conducted under a single protocol. It is preparing for a Phase 2b/3 trial.
Latest developments
In October 2025 the company appointed Robert J. Dempsey as Interim CEO following positive Phase 2 results and FDA alignment on its pivotal program. In November 2025 it announced plans to present 40-week topline Phase 2 data for migaldendranib and its recent FDA alignment at investor and ophthalmology meetings. In January 2026 it appointed George Montgomery as Executive Chairman to lead corporate development and strategic partnerships as it prepares for a Phase 2b/3 trial.
▸Full profile — market position, technology, go-to-market
Market position
The company positions itself in precision medicine across ophthalmology, neurology and inflammation, describing its hydroxyl dendrimer therapeutics as a new class of clinical-stage nanomedicine.
Technology
The company's platform is based on hydroxyl dendrimer (HD) technology, used to build precision nanomedicines that cross tissue barriers such as the blood-retinal barrier and are selectively taken up by inflamed tissue rather than healthy tissue. In the eye, the approach targets activated microglia, macrophages and retinal pigment epithelial cells with an anti-angiogenic payload. The lead ophthalmology asset, migaldendranib (MGB), is a subcutaneously administered next-generation tyrosine kinase inhibitor nanomedicine.
Go-to-market
Patients with ophthalmic, neurologic and inflammatory diseases, including diabetic macular edema, addressed through clinical development and regulatory pathways.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 2
by search overlap
Companies competing with Avttx for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 4
launches, deals, and filingsAshvattha Therapeutics appointed George Montgomery as Executive Chairman to lead corporate development and strategic partnerships as it prepares for a Phase 2b/3 trial of its next-generation TKI.
The company announced it would showcase 40-week topline results from the Phase 2 study of migaldendranib (MGB), a subcutaneous nanomedicine for diabetic macular edema, and recent FDA alignment at upcoming investor and ophthalmology meetings.
Ashvattha Therapeutics appointed ophthalmology veteran Robert J. Dempsey as Interim CEO following positive Phase 2 results and FDA alignment on its pivotal program.
The FDA agreed with the company's Phase 2b/3 clinical design, including the primary endpoint and development approach, providing a pathway to conduct two studies under a single protocol.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 1
primary sources listed
- Avttxavttx.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Avttx do?
- Ashvattha Therapeutics is a clinical-stage biopharmaceutical company developing hydroxyl dendrimer nanomedicines.
- Who are Avttx's investors?
- Avttx's investors include EcoR1 Capital, Evolution VC Partners, Helios Capital, Plum Alley Investments, Socii Capital, Tribe Capital Firstlook.